Skip to main content

Tweets

FDA has issued a drug safety warning for avacopan (Tavneos), dentifying 76 cases of drug-induced liver injury, including 7 cases of rare vanishing bile duct syndrome (VBDS). There were 8 deaths https://t.co/2GkYNg1Apn https://t.co/fW2qafKCew
Dr. John Cush @RheumNow ( View Tweet )
2 months 2 weeks ago
Myocarditis causes 17,000 deaths/Yr worldwide. Causes include A) iatrogenic/autoimmune: checkpoint inhibitors & gene therapy; B) High income countries: parvo B19, herpesvirus 6; C) low income: dengue, HIV, malaria and Trypanosoma cruzi (Chagas disease) https://t.co/0FjPyXygpz https://t.co/04J23AiqtK
Dr. John Cush @RheumNow ( View Tweet )
2 months 2 weeks ago
Target trial emulation: biologics or JAK vs RTX in RA-ILD -- abatacept (n=694), JAKi (156), IL-6i (389), or TNFi (734), PS-matched =# RTX; no significant differences (HR 0.74-1.09 NS) in outcomes of resp hosp, lung transplant & death. But ABA (HR 0.84) & JAKi (HR 0.62) had less https://t.co/c9IVwQYwMN
Dr. John Cush @RheumNow ( View Tweet )
2 months 2 weeks ago
What's it like to have RA? LISA: "It only took me three short years to go from rock climbing to a power wheel chair and that stage of the disease was frightening and painful and you feel hopeless and as if your life plan is being stolen from you. Once I was able to start https://t.co/d49htc8k4m
Dr. John Cush @RheumNow ( View Tweet )
2 months 2 weeks ago
Large pharmaceutical companies reduced their workforces by more than 22,000 employees in 2025. Among 17 largest companies , only five logged a head count increase in 2025 https://t.co/VdtlUaF4Q3 https://t.co/2xsCs9O1Tw
Dr. John Cush @RheumNow ( View Tweet )
2 months 3 weeks ago
Retrospective study of 1st SLE pregnancies from LUNA Registry. Fetal loss was associated w/ aPL (OR 2.46) & pulse steroids (2.46), but not w/ SSA Abs (1.32). 247 pregs, 194 live births, 53 fetal loss. Ro+ vs Ro- no difference in live births or preterm births https://t.co/bsMMvVyffw
Dr. John Cush @RheumNow ( View Tweet )
2 months 3 weeks ago
What's it like to have #RA? RICHARD: "There were days that I couldn’t mask the pain or hide the limp..So I tried to deny and hide the disease. I would always go up and down stairs when no one was looking. I got up extra early so no one could see me walk like an old man to the https://t.co/krHn4yoRYd
Dr. John Cush @RheumNow ( View Tweet )
2 months 3 weeks ago
5 Retrospective cohorts of PM/DM pts showed IIM (myositis) had signif higher risks of IIM patients HTN w/ pregnancy (OR 2.73), & C-section (OR 2.03). Also more preterm birth (3.7), SGA/IUGR (1.9) https://t.co/w6qymR0I2w https://t.co/ovtwdleRfE
Dr. John Cush @RheumNow ( View Tweet )
2 months 3 weeks ago
A new review of the GLP-1 receptor drugs @NEJM https://t.co/PK03jApZWB surprisingly, the word inflammation only appears once, in this diagram https://t.co/1PeBakBAQb
Eric Topol @EricTopol ( View Tweet )
2 months 3 weeks ago
Advanced Practice Rheum: Rheumatoid & Inflammation Testing In this review, we'll be talking about labs, inflammation, and tests for rheumatoid arthritis. https://t.co/UbEoBz37hT https://t.co/V9WzfRtbFQ
Dr. John Cush @RheumNow ( View Tweet )
2 months 3 weeks ago
Ixekizumab With Tirzepatide Efficacy in Obese Psoriatic Arthritis The TOGETHER-PsA trial has demonstrated the efficacy and safety of ixekizumab (IXE) administered with tirzepatide (TZP) in adult active psoriatic arthritis (PsA) patients who were overweight or obese. https://t.co/KFwfi9FaAh
Dr. John Cush @RheumNow ( View Tweet )
2 months 3 weeks ago
AAD 2026 Annual Mtg presents new data on another TYK2 inhibitor. In 2 phase 3 RCTs (ONWARD1 ONWARD2) envudeucitinib was superior to placebo & apremilast in 1700 plaque psoriasis pts https://t.co/DPlzDw5m7N

Dr. John Cush @RheumNow ( View Tweet )

2 months 3 weeks ago
×